In the recurrent setting and outside of clinical trials, it is not recommended to combine poly (ADP-ribose) polymerase (PARP) inhibitors with which of the following ovarian cancer therapies?

Chemotherapy
NTRK-targeted agents
Immunotherapy
All of the above

Congratulations to our October Winner!

B.C., Registered Nurse from NJ